CT-0594CP CAR-T Cells is under clinical development by CARsgen Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-0594CP CAR-T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-0594CP CAR-T Cells overview
CT-0594CP is under development for the treatment of relapsed, refractory multiple myeloma and plasma cell leukemia. It is a combination of CT0594 (BCMA-UCAR-T) and CT7590 (CD9-UCAR-T). CT0594 comprises of T cells which are genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing B cell maturation antigen (BCMA) and CT7590 comprises of T cells which are genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing CD9. It is administered through parenteral route and is being developed based on THANK (Target to Hinder the Attack of NK cells)-uCAR technology.
See Also:
CARsgen Therapeutics overview
CARsgen Therapeutics (CARsgen) operates as a clinical-stage immune-oncology company focused on developing Chimeric Antigen Receptor T cell therapies for cancer. Its pipeline product includes CAR-GPC3-T for the treatment of late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma; CAR-EGFR targeting Glioblastoma (GBM); CAR-CD19-T against lymphoma and B cell leukemia; CAR-Claudin18.2-T for gastric and pancreatic cancers; and CAR-BCMA-T against multiple myeloma. The company works in strategic partnerships with Shanghai Cancer Institute, Renji Hospital and Changhai Hospital. CARsgen is headquartered in Shanghai, China.
For a complete picture of CT-0594CP CAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
